Recent discussions on device complications have really highlighted the critical need for robust post-market surveillance. For instance, a recent study revealed that nearly 30% of complications were detected only after extensive monitoring beyond the initial trials. This emphasizes how ongoing data collection is essential not just for regulatory compliance, but for genuinely ensuring patient safety and device longevity.
I totally agree — ongoing data collection is essential not just for regulatory compliance, but for genuinely improving outcomes… We noticed significant complications popping up months after launch last year, so we’ve since implemented real-time monitoring to catch these issues sooner. It’s tough to balance resources, but it really can make a difference in patient safety.
It’s so true! I once worked on a device where we found a 20% increase in complications post-launch that didn’t show in the trials. It felt like finding the hidden calories in a seemingly healthy smoothie! @pClarke1992 makes a great point about the need for ongoing monitoring; it really can save lives.
I’ve seen firsthand how critical it’s to keep monitoring post-launch; it’s like checking your car’s oil after the first drive, you never know when it might need a top-up. @sullivan_73, we should definitely consider how our systems can adapt to these findings to improve patient outcomes.